| Journal | Clinical toxicology (Philadelphia, Pa.) |
| Study Type | Clinical Study |
| Population | Human participants |
This 5-year toxicology surveillance study provides critical baseline data on pediatric cannabis exposures as legalization expands access to higher-potency products. Understanding detection patterns helps clinicians anticipate presentations and guides appropriate laboratory workup in suspected pediatric ingestions.
Researchers analyzed over 6,000 urine specimens from pediatric patients with suspected toxic exposures across two hospitals over five years, comparing immunoassay screens with comprehensive gas chromatography-mass spectrometry analysis. Cannabinoids ranked among the most frequently detected substances via immunoassay (33% positive rate) and carboxy-THC was identified as one of the most common compounds detected by comprehensive analysis (85% detection rate). The study demonstrates the clinical reality that cannabis metabolites are commonly encountered in pediatric toxicology workups, reflecting broader societal access patterns.
“This data confirms what we’re seeing clinically—pediatric cannabis exposures are increasingly common and warrant systematic detection protocols. The high detection rates underscore the need for comprehensive toxicology screening when cannabis ingestion is suspected, as immunoassays alone may miss important co-exposures.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What percentage of pediatric patients with suspected toxic exposures test positive for cannabis?
- How reliable are standard urine immunoassay screens compared to comprehensive testing in pediatric toxicology cases?
- What are the most commonly detected substances in pediatric patients presenting with suspected ingestions?
- Should comprehensive toxicology testing be considered for all pediatric patients with suspected drug exposures?
- How do changes in cannabis legalization laws affect pediatric exposure patterns?
FAQ
What percentage of pediatric patients with suspected toxic exposures test positive for cannabis?
Cannabinoids were among the most frequently detected substances in immunoassay screens, which were positive in 33% of all specimens tested. Specifically, carboxy-tetrahydrocannabinol (THC metabolite) was identified as one of the most commonly detected compounds using comprehensive gas chromatography-mass spectrometry analysis.
How reliable are standard urine immunoassay screens compared to comprehensive testing in pediatric toxicology cases?
Standard immunoassay screens detected drugs in only 33% of specimens, while comprehensive gas chromatography-mass spectrometry detected substances in 85% of cases. This significant difference suggests that relying solely on immunoassay screening may miss many clinically relevant exposures in pediatric patients.
What are the most commonly detected substances in pediatric patients presenting with suspected ingestions?
The most frequently detected compounds included caffeine, nicotine, carboxy-tetrahydrocannabinol, antihistamines, antipyretics, antidepressants, antipsychotics, and anticonvulsants. Cannabis metabolites ranked as the third most common substance detected, highlighting the prevalence of cannabis exposure in this pediatric population.
Should comprehensive toxicology testing be considered for all pediatric patients with suspected drug exposures?
Given that comprehensive testing detected substances in 85% of cases compared to 33% with standard immunoassays, broader testing may be clinically warranted. The high detection rate with advanced methods suggests that standard screening may inadequately assess the scope of pediatric toxic exposures.
How do changes in cannabis legalization laws affect pediatric exposure patterns?
The study notes that changes in drug laws necessitate updated data on common exposures, with cannabis metabolites being among the top detected substances. This suggests that evolving cannabis accessibility may be contributing to increased pediatric exposures, requiring enhanced vigilance and appropriate testing protocols.